On May 18, 2026, Mettler-Toledo International Inc (MTD) shares rose 4.2%, closing at $1074.84. The stock has experienced significant volatility, trading within

Mettler-Toledo International Inc. (MTD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mettler-Toledo International NYSE: MTD reported first-quarter 2026 sales growth and higher adjusted earnings, with management citing solid execution, innovation and margin initiatives despite a more uncertain macroeconomic backdrop.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Although the revenue and EPS for Mettler-Toledo (MTD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MTD beats Q1 earnings estimates as sales increase 7% year over year, while management lifts full-year 2026 adjusted earnings guidance.

Mettler-Toledo (MTD) came out with quarterly earnings of $8.91 per share, beating the Zacks Consensus Estimate of $8.7 per share. This compares to earnings of $8.19 per share a year ago.

COLUMBUS, Ohio--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE: MTD) today announced first quarter results for 2026. Provided below are the highlights: Reported sales increased 7% compared with the prior year. In local currency, sales increased 3% compared with the prior year reflecting an increase of 1% excluding acquisitions. Net earnings per diluted share as reported (EPS) were $8.33, compared with $7.81 in the prior-year period. Adjusted EPS was $8.91, an increase of 9% over the p.

BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.

Massachusetts Financial Services Co. MA reduced its holdings in Mettler-Toledo International, Inc. (NYSE: MTD) by 7.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 167,872 shares of the medical instruments supplier's stock after selling 13,995 shares during